Literature DB >> 22580610

miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.

D Yin1, S Ogawa, N Kawamata, A Leiter, M Ham, D Li, N B Doan, J W Said, K L Black, H Phillip Koeffler.   

Abstract

Chromosome 1p36.23 is frequently deleted in glioblastoma multiforme (GBM). miR-34a localizes in this region. Our experiments found that miR-34a was often deleted and epidermal growth factor receptor (EGFR) was frequently amplified in genomic DNA of 55 GBMs using single-nucleotide polymorphism DNA microarray. Notably, we found that the mean survival time was significantly shortened for patients whose GBMs had both EGFR amplification and miR-34a deletion. Expression of miR-34a was significantly lower in GBM samples compared with normal brain tissue. Forced expression of miR-34a in GBM cells decreased their ability to migrate and profoundly decreased their levels of cyclin-A1, -B1, -D1, and -D3, as well as cyclin-dependent kinase and increased expression of cyclin kinase inhibitor proteins (p21, p27). Also, human GBM cells (U251) stable overexpressing mir-34a formed smaller tumors when growing as xenografts in immunodeficient mice compared with wild-type U251 GBM cells. Furthermore, the protein expression of EGFR decreased in the cells with forced overexpression of miR-34a. Additional studies showed that mir-34a targeted Yin Yang-1 (YY1) and YY1 is a transcription factor that can stimulate the expression of EGFR. Thus, our data suggest that miR-34a acts as a tumor suppressor by inhibiting growth of GBM cells in vitro and in vivo associated with moderating the expression of cell-cycle proteins and EGFR. Moreover, we discovered for the first time that both deletion of miR-34a and amplification of EGFR were associated with significantly decreased overall survival of GBM patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22580610      PMCID: PMC4085050          DOI: 10.1038/onc.2012.132

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

1.  Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis.

Authors:  Markus Kaller; Sven-Thorsten Liffers; Silke Oeljeklaus; Katja Kuhlmann; Simone Röh; Reinhard Hoffmann; Bettina Warscheid; Heiko Hermeking
Journal:  Mol Cell Proteomics       Date:  2011-05-12       Impact factor: 5.911

2.  Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets.

Authors:  Chiara Ghimenti; Valentina Fiano; Loredana Chiadò-Piat; Adriano Chiò; Paola Cavalla; Davide Schiffer
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

3.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

4.  Gene expression abnormalities in human glial tumors identified by gene array.

Authors:  J Y Ljubimova; N M Khazenzon; Z Chen; Y I Neyman; L Turner; M S Riedinger; K L Black
Journal:  Int J Oncol       Date:  2001-02       Impact factor: 5.650

5.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

6.  PTEN mutations in gliomas and glioneuronal tumors.

Authors:  E M Duerr; B Rollbrocker; Y Hayashi; N Peters; B Meyer-Puttlitz; D N Louis; J Schramm; O D Wiestler; R Parsons; C Eng; A von Deimling
Journal:  Oncogene       Date:  1998-04-30       Impact factor: 9.867

7.  CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.

Authors:  K Ueki; Y Ono; J W Henson; J T Efird; A von Deimling; D N Louis
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

8.  An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo.

Authors:  Michael T Hemann; Jordan S Fridman; Jack T Zilfou; Eva Hernando; Patrick J Paddison; Carlos Cordon-Cardo; Gregory J Hannon; Scott W Lowe
Journal:  Nat Genet       Date:  2003-02-03       Impact factor: 38.330

9.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.

Authors:  E E Schmidt; K Ichimura; G Reifenberger; V P Collins
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

10.  Identification of two contiguous minimally deleted regions on chromosome 1p36.31-p36.32 in oligodendroglial tumours.

Authors:  Z Dong; Jc-S Pang; M H Ng; W S Poon; L Zhou; H-K Ng
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more
  43 in total

1.  MiR-424 functions as a tumor suppressor in glioma cells and is down-regulated by DNA methylation.

Authors:  Chen Jin; Minhong Li; Yian Ouyang; Zhigang Tan; Yugang Jiang
Journal:  J Neurooncol       Date:  2017-05-15       Impact factor: 4.130

2.  The microRNAs miR-449a and miR-424 suppress osteosarcoma by targeting cyclin A2 expression.

Authors:  Ritu Shekhar; Priyanka Priyanka; Praveen Kumar; Tanushree Ghosh; Md Muntaz Khan; Perumal Nagarajan; Sandeep Saxena
Journal:  J Biol Chem       Date:  2019-01-24       Impact factor: 5.157

3.  MIR34A regulates autophagy and apoptosis by targeting HMGB1 in the retinoblastoma cell.

Authors:  Ke Liu; Jun Huang; Min Xie; Yan Yu; Shan Zhu; Rui Kang; Lizhi Cao; Daolin Tang; Xuanchu Duan
Journal:  Autophagy       Date:  2014-01-03       Impact factor: 16.016

Review 4.  MicroRNA and extracellular vesicles in glioblastoma: small but powerful.

Authors:  Arun K Rooj; Marco Mineo; Jakub Godlewski
Journal:  Brain Tumor Pathol       Date:  2016-03-11       Impact factor: 3.298

5.  Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1.

Authors:  T Que; Y Song; Z Liu; S Zheng; H Long; Z Li; Y Liu; G Wang; Y Liu; J Zhou; X Zhang; W Fang; S Qi
Journal:  Oncogene       Date:  2015-01-19       Impact factor: 9.867

6.  Human bone marrow-derived mesenchymal stem cell-secreted exosomes overexpressing microRNA-34a ameliorate glioblastoma development via down-regulating MYCN.

Authors:  Bin Wang; Zhong-Hua Wu; Ping-Yang Lou; Chang Chai; Shuang-Yin Han; Jian-Fang Ning; Ming Li
Journal:  Cell Oncol (Dordr)       Date:  2019-07-22       Impact factor: 6.730

7.  Multiplexed microRNA Expression Profiling by Combined Asymmetric PCR and Label-Free Detection using Silicon Photonic Sensor Arrays.

Authors:  Richard M Graybill; Maria C Cardenosa-Rubio; Hongwei Yang; Mark D Johnson; Ryan C Bailey
Journal:  Anal Methods       Date:  2018-03-23       Impact factor: 2.896

8.  Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activation.

Authors:  John M Furgason; Wenge Li; Brandon Milholland; Emily Cross; Yaqin Li; Christopher M McPherson; Ronald E Warnick; Olivier Rixe; Peter J Stambrook; Jan Vijg; El Mustapha Bahassi
Journal:  Mutagenesis       Date:  2014-08-06       Impact factor: 3.000

9.  MiR-135a and MRP1 play pivotal roles in the selective lethality of phenethyl isothiocyanate to malignant glioma cells.

Authors:  Taolan Zhang; Yingying Shao; Tang-Yuan Chu; Hsuan-Shun Huang; Yu-Ligh Liou; Qing Li; Honghao Zhou
Journal:  Am J Cancer Res       Date:  2016-05-01       Impact factor: 6.166

10.  miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression.

Authors:  Balabhadrapatruni V S K Chakravarthi; Darshan S Chandrashekar; Sumit Agarwal; Sai Akshaya Hodigere Balasubramanya; Satya S Pathi; Moloy T Goswami; Xiaojun Jing; Rui Wang; Rohit Mehra; Irfan A Asangani; Arul M Chinnaiyan; Upender Manne; Guru Sonpavde; George J Netto; Jennifer Gordetsky; Sooryanarayana Varambally
Journal:  Mol Cancer Res       Date:  2017-10-12       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.